Lexomil

Bromazepam, the active ingredient in Lexomil, is a benzodiazepine presented as an oral dosage form for oral administration. It is prescribed for the management of anxiety disorders and for short‑term relief of anxiety symptoms in adult patients and can be used under medical supervision.

GNH USA supplies Lexomil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory documentation and logistics support for bulk and unit‑dose requirements across multiple markets.

Bromazepam is used within the benzodiazepine class to treat conditions characterized by heightened anxiety and related symptoms. - Anxiety disorders: reduces excessive worry and tension, helping patients achieve calmer daily functioning. - Short‑term relief of anxiety symptoms: provides rapid symptom control during acute stress episodes or before procedures. - Adjunctive sedation: enhances sedation when combined with other agents for pre‑operative or diagnostic settings. - Pre‑operative anxiety: helps calm patients before surgery, reducing peri‑operative stress. - Procedural sedation: used as part of a sedation regimen for minor diagnostic procedures.

Bromazepam may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Drowsiness - Fatigue - Dizziness - Headache

Serious or Rare Side Effects: - Respiratory depression - Paradoxical agitation - Allergic reactions such as rash or anaphylaxis

When prescribing bromazepam, clinicians should observe several safety precautions to minimize risks. - Assess renal and hepatic function: evaluate before initiating therapy and adjust if impairment exists. - Avoid abrupt discontinuation: taper the dose gradually to prevent withdrawal symptoms. - Use caution in elderly patients: start with the lowest effective dose due to increased sensitivity. - Contraindicate concurrent alcohol use: alcohol may potentiate central nervous system depression. - Monitor for dependence and abuse: regular review of usage patterns is recommended. - Store at ambient temperature: keep tablets in the original container, protect from moisture and light.

Bromazepam can interact with other substances that affect the central nervous system or its metabolism.

Major Interactions (Avoid): - Opioids (e.g., morphine, oxycodone): combined use may cause profound respiratory depression. - Other benzodiazepines or sedative‑hypnotics: additive CNS depression increases risk of oversedation. - Alcohol: concurrent consumption enhances sedative effects and can be life‑threatening.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): may increase sedation; monitor patient response. - Antihistamines (e.g., diphenhydramine): can augment drowsiness and impair psychomotor performance. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise bromazepam plasma levels; dosage adjustment may be needed.